P57 The cost-consequence of fluticasone furoate/vilanterol 100/25 MCG in the uk using the results from the COPD salford lung study

Abstract

Introduction To support clinicians and healthcare organisations in their decision making on Chronic Obstructive Pulmonary Disease (COPD) related care, there is a need for studies conducted in patient populations which are representative of everyday clinical practice. The Salford Lung Study (SLS) is an open label prospective randomised controlled effectiveness trial (RCT). The study was conducted between 2012 and 2015. SLS investigated the effectiveness and safety of initiating treatment with once daily fluticasone furoate/vilanterol 100/25 microgram (FF/VI) compared with continuing with usual COPD maintenance treatment (usual care) in patients with COPD in an everyday clinical setting. Compared with usual care, FF/VI statistically significantly reduced the annual rate of moderate and severe exacerbations by 8.41% (NNT = 7) in the intention to treat population (>=1 exacerbation in previous 3 y; n = 2799), and in patients with >=1 exacerbation in previous 1 y; n = 2269). The current study estimates the potential economic impact of these results in a typical local UK payer environment. Methods A total of 1000 patients with COPD were included in an Excel based cost-consequence model. The model has a 1-year time-horizon. It was assumed that within one year the use of FF/ VI would increase from 5% to 20%. Mean annual rates of moderate/ severe exacerbations after twelve months for the ITT population were directly obtained from the RCT and included in the model (1.50 FF/VI and 1.64 usual care). Serious adverse events (SAEs) were excluded from the analysis. Costs were obtained.